Presentation is loading. Please wait.

Presentation is loading. Please wait.

Donald R. VanDevanter, David J. Pasta, Michael W. Konstan 

Published byくにもと ふくだ Modified over 6 years ago

Similar presentations

Presentation on theme: "Donald R. VanDevanter, David J. Pasta, Michael W. Konstan "— Presentation transcript:

1 Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis 
Donald R. VanDevanter, David J. Pasta, Michael W. Konstan  Journal of Cystic Fibrosis  Volume 14, Issue 6, Pages (November 2015) DOI: /j.jcf Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

2 Journal of Cystic Fibrosis 2015 14, 763-769DOI: (10. 1016/j. jcf. 2015
Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

3 Fig. 1 Disposition of covariates for Cox proportional hazards regression. A total of 65 covariates (gray shaded area) were analyzed by univariate Cox proportional hazards regression and sorted by P value. Among 25 covariates with P<.10 (upper box), 5 were discarded for reasons shown (middle box) and 20 were retained for modeling (bottom box). Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

4 Fig. 2 Kaplan–Meier survival plots of time to next PEx by prior-year PEx. Survival curves are shown for time from the end of PEx treatment to either censor (vertical dashes) or next PEx care episode stratified by the number of PEx care episodes experienced in the prior calendar year (in text at the end of each curve). Numbers of patients remaining at risk for PEx in each group are shown below the figure. Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

5 Fig. 3 Forest Plot of final Cox Proportional hazards regression model. Four categorical variables and two continuous variables remaining from the original 20 retained covariates (Fig. 1) after backwards selection with a requirement of covariate P<.01. Point estimates and associated P-values for covariates are shown. Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

6 Fig. 4 Covariate distributions by prior-year PEx subgroup. Percentages of all patients (vertical dashes), and prior-year PEx patient subgroups (circles) in which categorical covariates included in Cox proportional hazards regression (Fig. 1) was positive. Journal of Cystic Fibrosis  , DOI: ( /j.jcf ) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Download ppt "Donald R. VanDevanter, David J. Pasta, Michael W. Konstan "

Similar presentations

Survival After Single Versus Bilateral Lung Transplantation for High-Risk Patients With Pulmonary Fibrosis  Eric S. Weiss, MD, MPH, Jeremiah G. Allen,

Survival After Single Versus Bilateral Lung Transplantation for High-Risk Patients With Pulmonary Fibrosis  Eric S. Weiss, MD, MPH, Jeremiah G. Allen,
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis  Donald.

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis  Donald.
Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations 

Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations 
Treatment compliance in children and adults with Cystic Fibrosis

Treatment compliance in children and adults with Cystic Fibrosis
Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis  Cori Daines, Donald VanDeVanter,

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis  Cori Daines, Donald VanDeVanter,
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort  Margaret Rosenfeld, Julia Emerson, Sharon McNamara,

Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort  Margaret Rosenfeld, Julia Emerson, Sharon McNamara,
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation.

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation.
Mannose-binding lectin gene as a modifier of the cystic fibrosis phenotype in Argentinean pediatric patients  Luis Pablo Gravina, Carolina Crespo, Hilda.

Mannose-binding lectin gene as a modifier of the cystic fibrosis phenotype in Argentinean pediatric patients  Luis Pablo Gravina, Carolina Crespo, Hilda.
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
Complications of long and intermediate term venous catheters in cystic fibrosis patients: A multicenter study  Teresa L. May, Alex H. Gifford, Thomas.

Complications of long and intermediate term venous catheters in cystic fibrosis patients: A multicenter study  Teresa L. May, Alex H. Gifford, Thomas.
Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.

A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis  M. Proesmans, F. Vermeulen,

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis  M. Proesmans, F. Vermeulen,
Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.

Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint  D.R. VanDevanter, A. Yegin, W.J. Morgan,

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint  D.R. VanDevanter, A. Yegin, W.J. Morgan,
Statistical limitations of percent ideal body weight as measure for nutritional failure in patients with cystic fibrosis  T.O. Hirche, H. Hirche, S. Jungblut,

Statistical limitations of percent ideal body weight as measure for nutritional failure in patients with cystic fibrosis  T.O. Hirche, H. Hirche, S. Jungblut,

Similar presentations

Ads by Google